Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Burstein · SciRah

Researcher profile · Semantic Scholar

H. Burstein

Share profile

H. Burstein — researcher profile on SciRah

h-index: 89
Works: 417
Citations: 38K

Most-cited papers

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
W. Gradishar, M. Moran, J. Abraham, R. Aft +33 more
2022The Journal of the National Comprehensive Cancer Network797 citations
Semantic Scholar
Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.
H. Burstein, G. Curigliano, S. Loibl, P. Dubsky +9 more
2019Annals of Oncology600 citations Open access
Semantic Scholar
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P. Francis, O. Pagani, G. Fleming, B. Walley +32 more
2018New England Journal of Medicine582 citations Open access
Semantic Scholar
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
H. Burstein, C. Lacchetti, Holly Anderson, T. Buchholz +8 more
2019Journal of Clinical Oncology539 citations
Semantic Scholar
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G. Curigliano, H. Burstein, Eric P. Winer, M. Gnant +50 more
2017Annals of Oncology514 citations Open access
Semantic Scholar
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
William J. Gradishar, Benjamin O. Anderson, R. Balassanian, Sarah Blair +29 more
2018The Journal of the National Comprehensive Cancer Network497 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
W. Gradishar, M. Moran, J. Abraham, V. Abramson +33 more
2023The Journal of the National Comprehensive Cancer Network420 citations Open access
Semantic Scholar
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium
J. Dietz, M. Moran, S. Isakoff, S. Kurtzman +15 more
2020Breast Cancer Research and Treatment341 citations Open access
Semantic Scholar
ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
P. Tarantino, G. Viale, M. Press, Xi-Chun Hu +28 more
2023Annals of Oncology307 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
W. Gradishar, M. Moran, J. Abraham, R. Aft +34 more
2021The Journal of the National Comprehensive Cancer Network266 citations Open access
Semantic Scholar
Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update
H. Burstein, M. Somerfield, D. Barton, Ali Dorris +10 more
2021Journal of Clinical Oncology253 citations Open access
Semantic Scholar
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
H. Burstein
2020New England Journal of Medicine232 citations
Semantic Scholar
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
E. Mayer, A. Dueck, Miguel Martín, G. Rubovszky +40 more
2021The Lancet Oncology214 citations
Semantic Scholar
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
M. Gnant, A. Dueck, S. Frantal, Miguel Martín +36 more
2021Journal of Clinical Oncology206 citations Open access
Semantic Scholar
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
S. Tolaney, P. Tarantino, N. Graham, N. Tayob +26 more
2023The Lancet Oncology170 citations
Semantic Scholar
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G. Curigliano, H. Burstein, E. Winer, M. Gnant +50 more
2019Annals of Oncology142 citations Open access
Semantic Scholar
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
O. Pagani, B. Walley, G. Fleming, M. Colleoni +22 more
2022Journal of Clinical Oncology138 citations Open access
Semantic Scholar
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
J. Heymach, L. Krilov, A. Alberg, N. Baxter +18 more
2018Journal of Clinical Oncology113 citations
Semantic Scholar
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
S. Tolaney, N. Tayob, C. Dang, D. Yardley +43 more
2021Journal of Clinical Oncology111 citations
Semantic Scholar
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
M. Colleoni, W. Luo, P. Karlsson, J. Chirgwin +248 more
2018The Lancet Oncology97 citations Open access
Semantic Scholar
Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
H. Burstein, A. DeMichele, M. Somerfield, N. L. Henry
2023Journal of Clinical Oncology91 citations Open access
Semantic Scholar
Functional Decline and Resilience among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
A. Hurria, E. Soto-Pérez-de-Celis, Jacob B. Allred, H. J. Cohen +16 more
2018Journal of The American Geriatrics Society89 citations Open access
Semantic Scholar
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
E. Mayer, Yue Ren, N. Wagle, R. Mahtani +25 more
2024Journal of Clinical Oncology83 citations
Semantic Scholar
Breast Cancer, Version 3.2022
W. Gradishar, M. Moran, J. Abraham, R. Aft +33 more
202281 citations
Semantic Scholar
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
H. Burstein, C. Lacchetti, J. Griggs
2019Journal of Oncology Practice77 citations Open access
Semantic Scholar
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
H. Muss, M. Polley, D. Berry, Heshan Liu +24 more
2019Journal of Clinical Oncology64 citations Open access
Semantic Scholar
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
P. Francis, G. Fleming, I. Láng, E. Ciruelos +23 more
2022Journal of Clinical Oncology59 citations Open access
Semantic Scholar
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
H. A. Parsons, T. Blewett, X. Chu, S. Sridhar +25 more
2023Annals of Oncology58 citations Open access
Semantic Scholar
Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.
M. Magbanua, L. Hendrix, T. Hyslop, W. Barry +28 more
2020Journal of the National Cancer Institute49 citations Open access
Semantic Scholar
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
A. Grinshpun, S. Tolaney, H. Burstein, R. Jeselsohn +1 more
2023npj Breast Cancer46 citations Open access
Semantic Scholar
Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
E. Mayer, Yue Ren, N. Wagle, R. Mahtani +24 more
2023Cancer Research37 citations
Semantic Scholar
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
Kathryn J. Ruddy, Yue Zheng, N. Tayob, Jia-Ni Hu +41 more
2021Breast Cancer Research and Treatment36 citations
Semantic Scholar
Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy.
C. Mayerhofer, M. Sedrak, J. Hopkins, Tian-Yu Li +19 more
2023Journal of the National Cancer Institute35 citations Open access
Semantic Scholar
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes
M. Hassett, Hui Li, H. Burstein, R. Punglia
2020Breast Cancer Research and Treatment34 citations
Semantic Scholar
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
K. Ribi, W. Luo, B. Walley, H. Burstein +18 more
2020Breast Cancer Research and Treatment33 citations Open access
Semantic Scholar
Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
J. Bellon, Hao Guo, W. Barry, C. Dang +15 more
2019Breast Cancer Research and Treatment32 citations Open access
Semantic Scholar
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
E. Mayer, C. Fesl, D. Hlauschek, L. García-Estévez +29 more
2022Journal of Clinical Oncology28 citations Open access
Semantic Scholar
Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.
E. Mayer, S. Wander, M. Regan, A. DeMichele +8 more
201827 citations
Semantic Scholar
Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)
S. Tolaney, L. Trippa, W. Barry, Jia-Ni Hu +32 more
2020General Session Abstracts26 citations
Semantic Scholar
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
H. Parsons, T. Blewett, X. Chu, S. Sridhar +25 more
2023medRxiv25 citations Open access
Semantic Scholar
Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.
H. Parsons, H. Burstein
2020Journal of the American Medical Association (JAMA)25 citations
Semantic Scholar
Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer.
J. Bellon, N. Tayob, David D. Yang, J. Tralins +8 more
2022International Journal of Radiation Oncology, Biology, Physics23 citations Open access
Semantic Scholar
The global landscape of treatment standards for breast cancer.
D. Trapani, Jean Yves Douillard, E. Winer, H. Burstein +8 more
2021Journal of the National Cancer Institute21 citations
Semantic Scholar
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer
R. Barroso-Sousa, I. Vaz-Luís, A. di Meglio, Jia-Ni Hu +18 more
2021The Oncologist21 citations Open access
Semantic Scholar
Molecular Testing in Breast Cancer.
J. Litton, H. Burstein, N. Turner
2019American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting20 citations
Semantic Scholar
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
G. Pfeiler, D. Hlauschek, E. Mayer, C. Deutschmann +47 more
2023Journal of Clinical Oncology19 citations
Semantic Scholar
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
P. Tarantino, H. Burstein, N. Lin, I. Krop +7 more
2021Annals of Oncology15 citations Open access
Semantic Scholar
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)
J. Ligibel, L. Huebner, H. Rugo, H. Burstein +9 more
2021JNCI Cancer Spectrum15 citations Open access
Semantic Scholar
Multidisciplinary considerations in the treatment of triple‐negative breast cancer
J. Bellon, H. Burstein, E. Frank, E. Mittendorf +1 more
2020Ca15 citations Open access
Semantic Scholar
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
R. Barroso-Sousa, P. Tarantino, N. Tayob, C. Dang +45 more
2022npj Breast Cancer14 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Winer×21
Invite
E. Winer — researcher profile on SciRah
H. Rugo×16
Invite
H. Rugo — researcher profile on SciRah
S. Tolaney×13
Invite
S. Tolaney — researcher profile on SciRah
A. Partridge×13
Invite
A. Partridge — researcher profile on SciRah

×12

Invite

A. Wolff — researcher profile on SciRah

Invite

C. Dang — researcher profile on SciRah

Invite

S. Isakoff — researcher profile on SciRah

Invite

E. Mayer — researcher profile on SciRah

Invite

M. Colleoni — researcher profile on SciRah

Invite

M. Regan — researcher profile on SciRah

Invite

L. Carey — researcher profile on SciRah

A. DeMichele×9

Invite

A. DeMichele — researcher profile on SciRah